Skyhawk Therapeutics, Inc. has expanded its facilities with its new state-of-the-art labs in Superlab Suisse, in Basel Switzerland.

"Skyhawk has achieved tremendous scientific advances in our Basel Switzerland location so far," said Sergey Paushkin, Chief Scientific Officer of Skyhawk Therapeutics.

"This new space helps us grow our gifted senior scientific team and capabilities as we work to revolutionize disease treatment and develop therapies for some of the world's most intractable diseases," Paushkin added.

"This is an exciting time at Skyhawk. With our first program for Huntington's disease progressing in the clinic and our second program, SKY-1214, on track to enter the clinic, we've doubled our lab space in Basel to drive a series of promising INDs. Superlab Suisse is a leading provider of innovative research space and the largest private lab space in Switzerland, with a mission to provide dynamic infrastructure for Switzerland's life sciences sector. Skyhawk is delighted to be part of this growing biotechnology hub in Basel," said Clint Musil, Chief Executive Officer of Skyhawk Therapeutics.

Skyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient treatment for some of the world's most intractable diseases.

Skyhawk's discovery expertise is rooted in its proprietary drug discovery platform, which is designed to assess, identify, and test RNA splicing targets and small molecules across a broad range of therapeutic areas and disease states. Skyhawk has built collaborations with BMS, Biogen, Genentech, Merck, Sanofi, Takeda, Vertex, and Ipsen that leverage Skyhawk's novel platform across disease areas including neurodegenerative disease, autoimmune disease, and oncology.